Pathkey’s TrialKey Wins Paradigm Contract After Phase 3 Trial Misses Interim Threshold
PKY: $0.015 -6.25% · MC: $20M
Pathkey.AI says its TrialKey subsidiary has signed a services agreement with Paradigm Biopharmaceuticals, which is in voluntary administration, to independently assess whether trial design, conduct or analysis could have affected the interim result of Paradigm’s Phase 3 osteoarthritis study; the study did not meet its pre-set threshold to continue, and the outcome remains unchanged. The contract is valued at approximately $25,000 plus GST, and Pathkey says the work turns TrialKey’s broader offering into contracted project work. Internal retrospective testing also showed improved predictive performance, while further capabilities remain under testing or client validation.

Comments